Inhibikase Therapeutics Inc
IKT1.600USD
+0.080+5.26%
收盘 08/04, 16:00（美东）报价延迟15分钟
118.95M总市值
亏损市盈率 TTM
关于 Inhibikase Therapeutics Inc 公司
Inhibikase Therapeutics, Inc. 是一家临床阶段制药公司。该公司专注于开发帕金森病和相关疾病的治疗方法。其多治疗管线主要关注神经退行性疾病，其领先项目 risvodetinib（也称为 IkT-148009）是一种 Abelson 酪氨酸激酶 (c-Abl) 抑制剂，旨在治疗大脑内外的帕金森病以及由 Ableson 酪氨酸激酶引起的其他疾病。其多治疗管线正在研究与帕金森病相关的大脑和胃肠道疾病、与帕金森病相关的孤儿适应症（如多系统萎缩）以及激酶抑制剂的药物输送技术，例如 IkT-001Pro，它是抗癌药物甲磺酸伊马替尼的前体药物。该公司的 RAMP 药物化学项目已经确定了 IkT-148009 的多种后续化合物，可潜在地应用于大脑的其他认知和运动功能疾病。
公司简介
公司代码IKT
公司名称Inhibikase Therapeutics Inc
上市日期Dec 23, 2020
CEOMr. Mark T. Iwicki
员工数量15
证券类型Ordinary Share
年结日Dec 23
公司地址1000 N. West Street, Suite 1200
城市WILMINGTON
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编19801
电话13022953800
网址https://www.inhibikase.com/
公司代码IKT
上市日期Dec 23, 2020
CEOMr. Mark T. Iwicki
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Roberto Bellini
Mr. Roberto Bellini
Independent Director
Independent Director
1.46M
--
Mr. Vincent E. (Vince) Aurentz
Mr. Vincent E. (Vince) Aurentz
Independent Director
Independent Director
893.54K
--
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Chairman of the Board
Independent Chairman of the Board
431.81K
--
Mr. Arvind Kush
Mr. Arvind Kush
Independent Director
Independent Director
145.00K
--
Mr. David Mcintyre
Mr. David Mcintyre
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
10.29K
--
Dr. John Adams, Ph.D.
Dr. John Adams, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Dennis N. Berman
Mr. Dennis N. Berman
Independent Director
Independent Director
--
--
Dr. Roy Freeman, M.D.
Dr. Roy Freeman, M.D.
Independent Director
Independent Director
--
--
Mr. Mike Moyer
Mr. Mike Moyer
Managing Director of LifeSci Advisors
Managing Director of LifeSci Advisors
--
--
Mr. David Canner, Ph.D.
Mr. David Canner, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Roberto Bellini
Mr. Roberto Bellini
Independent Director
Independent Director
1.46M
--
Mr. Vincent E. (Vince) Aurentz
Mr. Vincent E. (Vince) Aurentz
Independent Director
Independent Director
893.54K
--
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Chairman of the Board
Independent Chairman of the Board
431.81K
--
Mr. Arvind Kush
Mr. Arvind Kush
Independent Director
Independent Director
145.00K
--
Mr. David Mcintyre
Mr. David Mcintyre
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
10.29K
--
Dr. John Adams, Ph.D.
Dr. John Adams, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月18日 周日
更新时间: 5月18日 周日
持股股东
股东类型
持股股东
持股股东
占比
Sands Capital Ventures LLC
14.73%
Soleus Capital Management, L.P.
8.51%
Fairmount Funds Management LLC
8.24%
Perceptive Advisors LLC
7.97%
SP IKT Holdings LLC
7.86%
Other
52.70%
持股股东
持股股东
占比
Sands Capital Ventures LLC
14.73%
Soleus Capital Management, L.P.
8.51%
Fairmount Funds Management LLC
8.24%
Perceptive Advisors LLC
7.97%
SP IKT Holdings LLC
7.86%
Other
52.70%
股东类型
持股股东
占比
Hedge Fund
50.16%
Private Equity
7.97%
Corporation
7.86%
Investment Advisor
5.87%
Individual Investor
5.17%
Investment Advisor/Hedge Fund
4.94%
Research Firm
0.73%
Pension Fund
0.08%
Other
17.23%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
84
61.53M
82.77%
+5.93M
2025Q1
82
60.21M
81.40%
+7.53M
2024Q4
61
58.78M
83.36%
+15.59M
2024Q3
38
1.99M
24.34%
-203.16K
2024Q2
42
2.13M
28.26%
+379.22K
2024Q1
47
1.51M
21.65%
-625.47K
2023Q4
49
1.53M
25.68%
-638.36K
2023Q3
54
2.02M
35.52%
-749.23K
2023Q2
55
2.34M
41.60%
-408.30K
2023Q1
53
2.33M
44.43%
-243.35K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Sands Capital Ventures LLC
10.95M
14.73%
--
--
May 01, 2025
Soleus Capital Management, L.P.
6.33M
8.51%
--
--
Mar 31, 2025
Fairmount Funds Management LLC
6.13M
8.24%
--
--
Mar 31, 2025
Perceptive Advisors LLC
5.92M
7.97%
--
--
Mar 31, 2025
SP IKT Holdings LLC
5.84M
7.86%
+5.84M
--
Oct 21, 2024
Commodore Capital LP
5.34M
7.19%
-580.57K
-9.80%
Mar 31, 2025
Adar1 Capital Management LLC
5.12M
6.89%
+19.10K
+0.37%
Mar 31, 2025
The Vanguard Group, Inc.
2.85M
3.83%
+10.02K
+0.35%
Mar 31, 2025
Nantahala Capital Management, LLC
2.19M
2.95%
--
--
Mar 31, 2025
Blackstone Alternative Asset Management, L.P.
2.07M
2.79%
--
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Value ETF
0.01%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
iShares Micro-Cap ETF
占比0.02%
iShares Russell 2000 Value ETF
占比0.01%
ProShares Hedge Replication ETF
占比0%
iShares Russell 2000 ETF
占比0%
iShares Russell 2000 Growth ETF
占比0%
Global X Russell 2000 ETF
占比0%
Proshares Ultra Russell 2000
占比0%
ProShares UltraPro Russell2000
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Jun 29, 2023
Merger
6<1
Jun 29, 2023
Merger
6<1
Jun 29, 2023
Merger
6<1
Jun 29, 2023
Merger
6<1
公告日期
类型
比率
Jun 29, 2023
Merger
6<1
Jun 29, 2023
Merger
6<1
Jun 29, 2023
Merger
6<1
Jun 29, 2023
Merger
6<1
